Listening for arrhythmias

Enabling mass prevention of strokes and chronic complications over time in at-risk populations using voice-based markers for telemonitoring & screening

What is Cardiokol?

Cardiokol software applications for smart devices and telecom clouds enable practical, economical, prolonged mass tele-screening for dangerous, asymptomatic heart arrhythmias. Timely detection and management (with oral drugs) of arrhythmia, such as AF, can prevent over 70% of AF-related strokes and other chronic, high-cost complications.
icon_heart

About Us

Cardiokol is a privately-owned digital telehealth company that develops voice-based markers and methods for monitoring and screening heart rhythm disorders in large at-risk populations.

We offer revolutionary affordable, scalable, long-term and age-friendly monitoring solutions.

Our technology is applicable for mass at-risk populations including older adults (65+), by utilizing proprietary technology that is implemented in speech platforms such as landlines, smartphones, smart speakers and voice assistants.

Our Technology

‍Cardiokol technology extracts and identifies vocal parameters that are associated with the irregularity of heartbeat.

Our proprietary algorithms are based on explicit signal processing techniques and artificial intelligence (neural networks models) that were established with our growing clinical database of Atrial Fibrillation and normal heart rhythm vocal recordings with matched ECG patient recordings.

diagram_cardiokol

The Cardiokol Solution

Proprietary software-based solutions to scale AF detection, based only on voice

1. Input:
Voice Signal

cardiokol_icon_voice

2. Voice Analyser
& Risk Assessment

cardiokol_icon_voice_analyser

3. Output:
Atrial Fibrillation Detection

cardiokol_af_detection
cardiokol_ce
cardiokol_icon_isocardiokol_icon_isocardiokol_icon_iso
cardiokol_patent

Benefits

cardiokol_Adaptable

Adaptable

Eliminating the need to wear a device and handle new technology - with adaptable age-inclusive (primarily elderly-friendly) technology.

cardiokol_Affordable

Affordable

Our application is cost-effective and does not require hardware or special equipment.

cardiokol_Scalable

Scalable

Our detection capability via telecom networks is designed to provide remote mass-monitoring over time to hundreds of millions of older adults at risk.

cardiokol_Far-reaching_solution

Far-reaching solution

04

Our technology is compatible with a wide range of voice interfaces such as voice-activated assistants, smartphones, and any other method that produces a voice signal.

Research

Our current study & pilot streams consist of:

cardiokol_icon

3 Clinical studies

cardiokol_icon

12 Medical Centres

cardiokol_icon

Community pilot with patients at home

cardiokol_icon

Patent no. US 11,398,243 B2  has been granted in USA

3 Patents Pending

cardiokol_research

Published Research 1

Cardiokol’s clinical development involves several medical centers.

The interim results of one of our completed multicenter study with 143 patients was presented in the European Society of Cardiology Congress in 2019.

Learn more about the study

Peer reviewed paper:
”Automated detection of atrial fibrillation based on vocal features analysis” - Journal of Cardiovascular Electrophysiology



We are very excited to share this multicenter study.

This clinical trial demonstrates that human voice carries information related to arrhythmias, and specifically to Atrial fibrillation (AFib) the most common cardiac arrhythmia.

Cardiokols' proprietary algorithm analyses the patients' voice to detect potential AFib.

Learn more about the results of research
cardiokol_research

Grants

cardiokol_grants
cardiokol_grants
cardiokol_grants
cardiokol_grants

Executive Team

James Amihood, CEO

25 years of management experience including CEO of PRM Inc., GM of Syqe Medical and senior positions at multinational pharmaceutical and healthcare companies (Teva, Schering Plough, Perrigo), managing subsidiaries and heading BD and M&A. BSc Chemistry, BSc IE, MBA

Alon Goren, Executive Chairman
& co-Founder

Experienced innovator, entrepreneur, leader and strategist in the health-tech ecosystem. Founder and former CEO of Endymed (a publicly-traded group of biomed companies) from idea to global sales, IPO, M&A and Int'l awards.
Acting as Board director/advisor to health-tech and other companies, academic and medical institutions. BSc EE, MSc BME, MBA, post-MBA and Board directors’ advanced programs

Yirmi Hauptman, CTO
& co-Founder

Experienced chief technology officer, over 20 years of experience in signal processing of speech signals including medical application. Former CTO and founder of Cellvine and Galsafe. MSc EE

Eli Attar , COO, VP R&D
& co-Founder

Over 20 years as technology and engineering executive of serval telecom companies and mega projects. Former Chief engineer Alcatel Israel, Director BD architecture & solutions Alcatel-lucent, VP Engineering Trilogical. BSc EE, MBA

Pini Sabach, Co-founder, Chief Collaborations & Cyber Security Officer

Experienced in variety of entrepreneurial and management positions. Founder & former CEO, Celerica, GalSafe, Pallasium. BA, PEE

Investors

cardiokol_investors


Gilles Pagniez


cardiokol_investors

Stéphane Guinet

KAMET Founder and CEO
Former CEO of AXA Global Direct

cardiokol_investors

Ron Shamir

Phonetica Co-founder & CEO

cardiokol_investors

Michael Niddam

KAMET Co-Founder and Managing Partner
Former Partner at Boston Consulting Group

Advisory Board

Prof. Robert Fishel

Medical Advisor
President and founder of Florida Electrophysiology Associates
Founder and Director of the Electrophysiology department at JFK Hospital, Atlantis

Prof. Michael Eldar

Medical Advisor
Cardiologist; former Director of Sheba MC’s Heart Center, EP Dept. and Heart Research Inst.; Chair of Cardiology, Sackler School of Medicine, TA


Jon Otterstatter

Senior Advisor
General Manager – Preventice( Boston Scientific)
Co-Founder, Chief Executive Officer, Preventice Solutions

Prof. Amir Lerman

Medical Advisor
Cardiologist, Director, Chest Pain and Coronary Physiology Clinic; Unit, Mayo Clinic

Dr. Gregory Golovchiner

Medical Advisor, Cardiologist
Head of the Electrophysiology Unit, Rabin MC

Prof. Natan Bornstein MD

Medical Advisor, Strokologist
Head of the Stroke Unit, Shaare Zedek MC
Former VP World Stroke Association


Dr. Amir Beker

Senior Advisor
Founder & CEO TASE:BSP

Yoav Rubinstein

Senior Advisor
Former CEO SHL Global (SWX:SHLTN)

Israel Schreiber

Senior Advisor
Former CEO, Healthwatch, Ornim Medical,
Itamar Medical (NSDQ:ITMR)

News

We‘re looking forward to meeting you at #ces2023 See you at our Booth # 62000 (kiosk 22)

Cardiokol is amongst the 12 finalists in the startup competition at MEDICA - Leading International Trade Fair 2022 !We are proud to be selected from almost 250 international startups and have the opportunity to present our "Voice Assist Arrhythmia Monitoring" solution - VAAM and how voice can save lives.

Join us on 15 Nov 22 (13:00 – 15:00 CET) at the Pitch and Award Ceremony.Also meet us between 14-17 Nov at the Israeli Export Institute pavilion, Hall 16 J38, Booth no.6.

Cardiokol is proud to announce we were selected from hundreds of competing companies as a Rising Star Finalist in the Consumer Prevention category for a 2022 Digital Health Award.

The UCSF Health Hub Digital Health Awards honor outstanding health technologies and innovations dramatically transforming healthcare, so we are especially honored to be considered for this prestigious award.

The Rising Star track is new this year, recognizing up-and-coming companies to watch in the digital health space.

Join us for a conversation with the finalists, Wednesday 10/26 at 11 am PST on Zoom.

Registration link:
Meet us:
HLTH 2022 | Nov 13 - 16 | Las Vegas
Bayer G4A Pavilion | Booth # 557-16 |
Show floor (Level 2, The Venetian Expo & Convention Center)


Thank you, David Dansereau and Michael Garrow for hosting our CEO James Amihood on the latest Know Stroke Podcast!

Learn how voice technology can detect life-threatening arrhythmia's and save lives. Listen to the episode below:
Using Voice to Save Lives: Interview with James Amihood, CEO of Cardiokol

This episode can also be watched on YouTube:
Know Stroke Podcast Interview with James Amihood, CEO Cardiokol

Early-stage healthtech start-up Cardiokol is developing technology that listens to the sound of a patient’s voice over a mobile phone, landline phone or smart speaker to detect and analyze vocal biomarkers that indicate that the patient may be suffering from disease. The voicetech co is proving its case first in detecting arrhythmias, which are often asymptomatic and usually go undetected until they’ve led to a more serious issue like a stroke.

Cardiokol’s CEO James Amihood explains the tech behind this first use case – which already has one US patent granted and is pending approval on three more – and his plans to expand the company’s base of vocal biomarkers to enter into new disease states and new markets. The company is currently raising a Series A funding round and is planning to expand from Israel and Europe to the US. How could the technology change the game for disease prevention, starting with strokes? James connects the dots to the big vision for the company’s future as he explains how Cardiokol’s tech is already providing those most at-risk of arrythmia a very cost-effective, simple-to-use way to screen and monitor their long-term heart health.

We are very excited to attend the HLTH 2022 Conference
in Las Vegas! Health innovation's largest conference and ecosystem in the United States.

We are honored to be part of the Bayer G4A delegation this year, collaborating and sharing ideas about how remote monitoring and digital health will transform the healthcare industry.

Our team looks forward to meeting you there, sharing our story about how voice technology can be used to screen and monitor cardiac conditions such as Atrial Fibrillation and most importantly to save lives.

Special thanks to the Bayer G4A team for their support and joining forces.

TH 2022 | Nov 13 - 16 | Las Vegas
Bayer G4A Pavilion | Booth # 2462-10 |
Show floor (Level 2, The Venetian Expo & Convention Center)

We are very proud to announce our latest patent has been granted by the United States Patent and Trademark Office (PTO): Patent No. 11,398,243 for “Verbal Periodic Screening for Heart Disease”.

This patent greatly strengthens our intellectual property position in the digital telemonitoring field and further demonstrates the huge potential of our voice-based platform technology for screening and monitoring of cardiac conditions such as Atrial Fibrillation!

Read more about the technology

We will be at Medica 2022!

This year we will be exhibiting at the most significant event in the #medical sector, as part of the Israeli export institute delegation.

This is a major step for Cardiokol appearing on an international stage, and exploring business opportunities on a large scale.We will be there to tell the story of saving lives by using voice, and with almost 50,000 visitors from more than 150 countries - we believe this story will receive major coverage.

To schedule a meeting with us, click here:

We're excited to announce that we will be exhibiting at CES2023!

It's a real pleasure to be a part of the most influential global tech event in the world!

We hope to see you there, and share with you our promising innovation on saving lives using voice technology.

Leave us a message, and we will be happy to set up a meeting  with you while you're there.

January 5-8, 2023
Hall G | Booth No. 61708

We are very excited to share this multicenter study.

This clinical trial demonstrates that human voice carries information related to arrhythmia, and specifically, to Atrial fibrillation (AFib) the most common cardiac arrhythmia.

Cardiokols' proprietary algorithm analyses the patients' voice to detect potential AFib.

The article was published in June 2022 in the Journal of Cardiovascular Electrophysiology

By Gregory Golovchiner MD | Michael Glikson MD | Moshe Swissa MD | Yaron Sela PhD | Aryeh Abelow MD | Olga Morelli MD | Amir Beker PhDAtrial fibrillation (AFib) is the most common persistent cardiac arrhythmia, affecting almost 40 million adults worldwide.
Early detection of afib before the occurrence of complications may result in effective treatment that may decrease stroke rate by more than 60%.

By Gregory Golovchiner MD | Michael Glikson MD | Moshe Swissa MD | Yaron Sela PhD | Aryeh Abelow MD | Olga Morelli MD | Amir Beker PhD

We invite you to read the abstract and watch video

Over-the-phone voice analysis detects atrial fibrillation

“The mother of one of our founders had a stroke due to A-fiband he couldn’t believe that the detection capability is so low - less than 10 percent,” says James Amihood, speaking with ISRAEL21c from the five-year-old company’s headquarters in Israel’s Airport City.

“He realized that there is an unmet need for a cost-effective way to monitor senior patients more frequently. And it must be age-friendly because older people don’t like wearables.”

Voice analysis was the answer that Cardiokol’s founders came up with (kol is Hebrew for “voice”).

Visit the following link to read the entire article - Over-the-phone voice analysis detects atrial fibrillation

Atrial Fibrillation can be detected from voice samples only!

We invite you to read a short article published lately at Healio,
where head of electrophysiology and pacing unit in the department of cardiology at Rabin Medical Center, Dr. Gregory Golovchiner is being interviewed regarding a recent study he led together with Prof. Moshe Swissa, head of electrophysiology and pacing unit in the department of cardiology at Kaplan Medical center, and Prof. Michael Glikson, Director of the Jesselson Integrated Heart Center of Shaare Zedek Medical Center in Jerusalem.

This is the first study to examine the correlation between voice features and atrial fibrillation.

As Dr. Golovchiner says, “The findings of this study open horizons for non-invasive, low-cost, age-friendly, prolonged and systematic monitoring of patients with known AF, as well as screening for AF in populations at risk.”

Read more

James Amihood, CEO of Cardiokol spoke to Health Tech World about voice analysis and how it can be used to detect atrial fibrillation

Read more

We've reached 500 followers on LinkedIn!

This is a great opportunity to thank you all for your support and interest in Cardiokol's mission to use our voice platform to save lives.

A very warm welcome to everyone who has joined us in recent months, and a special thanks to those who have been following us since the beginning!

Our aim is to promote awareness for afib (Atrial Fibrillation) prevention here on LinkedIn, share with you our journey in the field, and continue engaging with you.

We look forward to reaching new successful milestones!

We are proud to be selected among the six healthtech promising startups participating in the #5 cohort of Hadassah Accelerator and IBM Alpha Zone program. It’s all about accelerating Cardiokol's clinical, technological and business development.

By working closely with IBM Alpha Zone and Hadassah Accelerator, we bring the company closer to the clinicians, patients and real-world data, coupled with the best-of-breed technologies and advice of experts.

We are proud to announce our 8 finalists who were selected to participate in the Digital Health Accelerator program!

We had 100 companies apply and were so impressed with the groundbreaking technology that is being invented here in Israel. We know the next big thing in Digital Health will be from Haifa, and we are so excited to work with these 8 amazing companies to expand their ideas and change the world of healthcare.

We'd like to thank tech12, Oracle and Tal Shahaf for raising the awareness of Afib (Atrial Fibrillation) and Cardiokol voice technology for supporting the detection of Afib most common - often silent - heart arrhythmia and keystroke risk.James Amihood Cardiokol CEO said that "this age-friendliest technology has many benefits and it does not require the use of any special devices or wearables besides landline, mobile phone or digital voice assistant. It can easily be operated on a large scale, for example in call centers and telecom clouds to remotely access hard to reach and hardly reached populations as well."

Please read the full article in the following link
(for Hebrew readers only):

We are proud to share that we’ve been selected to be part of the JVP & Margalit Startup City Haifa - Digital Health Innovation program. It's an honor to be part of a group of companies developing cutting-edge digitalhealth technologies in order to save lives.

At the e-Health Investment Forum on June 15th, great companies will do their pitches LIVE on stage! Discover more about Cardiokol, Virtuleap, Braingaze and nen in the category growth live at the EHIF event.

Be sure to reserve your seat for the EHIF here:

Deeyook wins best overall pitch at Oracle Startup Idol Israel.

Six Israeli startups presented to a panel of top global industry analysts and influencers as part of the final event, with Cardiokol winning the most innovative solution, and UpNext GenZ's pitch being named as most creative.

Other finalists included: FutureEcom, Outgage and Ovo Automotive

Our G4A alumni company Cardiokol’s pitch has won the most innovative solution at Oracle Startup Idol Israel among six startups. Cardiokol is a #telehealth company that commercializes voice-based markers and technologies for enhanced identification and monitoring of common heart rhythm abnormalities in large populations at risk. Do you want to partner with Cardiokol? On June 23, you can join our G4A virtual DigitalHealthForum to meet Cardiokol among 20 of G4A's most promising alumni firms.

The G4A Alumni Expo will be open from June 23-30! Sign up here

We won Most Innovative Solution Oracle startup
Idol – Israeli edition!

Thank you to the industry analysts and influencers who voted for us. And thank you to the five other super impressive startups and founders who participated.

Read more about the competition:

On June 23, Bayer G4A will host the virtual #DigitalHealthForum and we are honored to be recognized as one of the most promising Bayer G4A alumni companies attending the G4A Alumni Expo.On May 17, we’ll pitch to industry analysts against five other super impressive startups for prizes of Most Creative, Most Innovative, and Best Overall. Stay tuned to see if we win.

We’ve been selected for Oracle Startup Idol – Israel edition!Title copy goes here

On May 17, we’ll pitch to industry analysts against five other super impressive startups for prizes of Most Creative, Most Innovative, and Best Overall. Stay tuned to see if we win.

Great welcome to our new team members: Alon Liberman and Gabriel Zackon, Algorithm Developers.

Great welcome to our new team members: madlin abbas, CRA and Inbar Zolkov, Algorithm Engineer & Project Manager.

Together we will further develop the ability to use voice in order to save lives!

Cardiokol Using Voice to Save Lives

During the pitch organized for the companies participating in H+ Digital Health Innovation Program, run by InsurTech Hub Munich, our CEO James Amihood presented some key estimated cost saving for #insurers, when using advanced technology solutions for detecting suspected AF.On May 17, we’ll pitch to industry analysts against five other super impressive startups for prizes of Most Creative, Most Innovative, and Best Overall. Stay tuned to see if we win.

"The estimated cost saving for the insurers in Germany is more than 1.5 billion euros a year”.

Please watch the 3 min. video to learn more about the unique value proposition of Cardiokol for insurers.

We're happy to inform you that Cardiokol was selected by the Israel Innovation Authority to exhibit in Biomed Israel 2022 Startup Pavilion on May 12th
(booth 31).

Biomed Israel conference is the leading event of Israel’s life sciences industry, and well positioned both in Israel and the international market.The conference brings together thousands of international visitors and reflects the most innovative solutions in the industry.In the pavilion you will be able to learn about the commercial product that Cardiokol offers for the detection of Atrial Fibrillation from speech, and future solutions will also be presented.

Insurance & Chronic Diseases:
How can insurers support chronic disease patients?

50% of the German population has a chronic disease. Demographic shifts and longer life expectancy have made chronic diseases a pressing topic, constantly challenging healthcare systems with increasing costs and affecting patients’ quality of life. We have asked Markus Buchhäusl, Head of Digitalization, Technology and Business Organization and Teresa Hoess, Healthcare Manager at ARAG to discuss with us the role of insurers in supporting chronic patients and their views on possible effective solutions.

A shoutout to all our chronic disease startups joining the H+ Digital Health Programme for bringing in personalized and engaging solutions to improve chronic diseases and the rehabilitation journey: Ampersand Health, Cardiokol, KINFINITY Solutions, medicalmotion GmbH, Mia-Care, Perfood, Sensely and TakesCare. Check out their amazing solutions!

Read more:

A Chat with James Amihood, CEO at Digital Telehealth Company: Cardiokol

Cardiokol CEO James Amihood recently sat down with Dana Leigh at TechRound to talk about the company and how they've developed voice-based markers and methods for monitoring and screening #heartrhythm disorders in large at-risk populations.We asked Yirmi: "What will the future of Cardiokol's VAAM (Voice-Assisted Arrhythmia Monitoring) look like?"

The company’s software applications ongoingly analyse daily voice samples through commonly-used voice-interfaces, to detect and track its proprietary vocal biomarkers of risky, treatable and “silent” health conditions.

To learn more about Cardiokol, check out the interview here

Join us on April 6th for InsurTech Hub Munich final HEALTH X INSURANCE SHOWCASE where cutting-edge solutions that support the insurers’ transformation from payor to health care partners will be presented.It has been an intense Innovation Programme and we can’t wait to pitch alongside other ambitious and inspiring startups from the H+ Digital Health Program and hear from healthcare experts like Bart De Witte - Hippo AI Foundation, Ludovic Pureur - Virgin Pulse, Dr. Olivier Flückiger - RoX Health, Peter Stockhammer - Generali Vitality, Francesca Tamma - Swiss Re and many more!

Want to join us? Register HERE to get your tickets

We're happy to introduce Yirmi Hauptman, CTO & Co-Founder at Cardiokol.

We asked Yirmi: "What will the future of Cardiokol's VAAM (Voice-Assisted Arrhythmia Monitoring) look like?"

Yirmi replied: "By simple voice analysis, experts will be able to:
1. Diagnose & monitor physical status, and provide an initial feedback
2. Track patients' health condition over time

For example, a patient will call an emergency medical center and as part of this initial call a voice app will analyse his/her voice, screen various health parameters and his/her condition and provide the doctor with essential information and recommendations for additional diagnosis. This is a mass screening solution for disease detection targeting large populations. This solution has high accessibility and is very cost-effective. In the future, I believe it will be integrated within personal phone assistants systems as well. It will save precious time for people who already have risk factors. Many companies are developing solutions in this field for various diseases while we at Cardiokol are uniquely focused on Afib to start. I think the main challenge here is the collection of data. It needs to be big and diversified enough in order to make this future forecast a reality.

My professional motto is: Speech contains more secrets than the text"

Targeted vs. full population screening costs for incident atrial fibrillation and AF-related stroke for a healthy population aged 65 years in the United KingdomProf. Natan Bornstein + Cardiokol

Recent publication in the European Heart Journal - titled "Targeted vs full population screening costs for incident Atrial Fibrillation and AF-related stroke for a healthy population aged 65 years in the United Kingdom" - has studied how an opportunistic #AF screening program would impact on #healthcare costs of AF (and AF-related stroke) for the NHS.

Study results show that "focusing on 2030 and should opportunistic screenings for AF be introduced at age 65, with subsequent treatment, it is predicted to reduce the number of stroke cases over the decade by 5,888 if all 65 year olds are screened and 695 if just the high risk group are screened. If the number of strokes can be reduced by treating these screened AF patients, we would substantially reduce the health and social care costs of stroke by £654.6m and £77.3m respectively."

Cardiokol's deviceless Voice-Assisted Arrhythmia Monitoring (VAAM) products are aimed at a more cost-effective mass-screening for AF burdens (associated with higher #stroke risk and clinical outcome than short AF episodes) in large, at-risk populations over the age of 65.

Why is it important to detect Atrial Fibrillation and other Arrhythmia early on?
Dr. Gregory Golovchiner, Medical Consultant to Cardiokol, explains

We're happy to share with you an interview translated from Hebrew with Dr. Gregory Golovchiner, recently published in Haaretz magazine.

Dr. Golovchiner, Head of the Electrophysiology and Pacing Unit at Rabin Medical Center, carried out research using Cardiokol's proprietary vocal biomarker software, in order to provide early detection of patients with suspected atrial fibrillation.
Dr. Golovchiner has been the company's medical consultant since its inception.

“The online application asks the patients to say ‘ahh’ three times a day, and the developed technology detects if they are having an atrial fibrillation episode. A smart scheduling algorithm that increases the accuracy of detection has also been developed. The technology can be embedded in different systems - from smartphones and landline phones to technology assistants like Siri and Alexa, etc. so that we can keep track of those who are at risk,“ he explains.

For further reading please click on the


We’re honored to be selected out of 270 applicants for the H+ Digital Health Innovation Program (https://lnkd.in/dQbev5s2), run by InsurTech Hub Munich, and join 19 global digital health companies in this unique and prestigious program.

The program was founded by the private insurance companies in Germany, whom are interested in promoting innovation in the digitalhealth area by initiating pilots with the program participants. For Cardiokol, it’s a great opportunity to cooperate with private insurance firms, and provide innovative software to detect new Atrial Fibrillation patients and save their lives.

Screening for atrial fibrillation: less is more?

We at Cardiokol had a very beneficial and fruitful time working with Bayer G4A team during the Growth Accelerator program over the last 10 weeks.

During this period we presented our vision and our unique Atrial Fibrillation vocal biomarker to support the saving of lives.
We look forward to continuing working with the great team at Bayer/G4A and to all the milestones we want to achieve together.

If you are a manager or an entrepreneur of a company in the field of digital health, we strongly encourage you to apply for one of the Bayer programs. This could be the best outcome for you in 2022!!
Thanks also to Brian Drozdowicz, Dominick Kennerson, Sophie P., Bayer G4A team & all external mentors/advisors for being such great hosts during the virtual event!

Reach out if you want to learn more about using voice to save lives.


Recent and notable clinical studies show that Afib monitoring based on twice daily tests (the Strokestop study) detects fewer Afib cases but at higher risk of stroke, while continuous monitoring (the LOOP study, using implantable monitor) detects shorter Afib episodes that are clinically less relevant.Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse tincidunt sagittis eros. Quisque quis euismod lorem. Etiam sodales ac felis id interdum.

In other words, daily Afib tests present a more cost-effective monitoring method, with more actionable steps (and clinical outcomes) vs continuous monitoring.Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse tincidunt sagittis eros. Quisque quis euismod lorem. Etiam sodales ac felis id interdum.

Cardiokol's first product for daily Afib tests is entirely aligned with these recent findings. Cardiokol's 'VAAM" (Voice Assisted Arrhythmia Monitoring) utilizes daily voice samples to detect the more dangerous and often "silent" Afib burdens, rather than any Afib episode, while using a most cost-effective and age-friendly manner.Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse tincidunt sagittis eros. Quisque quis euismod lorem. Etiam sodales ac felis id interdum.

For further reading, see:

Screening for atrial fibrillation: less is more?

We have been accepted for the very exciting Bayer G4A partnerships Program for 2021" We are very proud and excited in being selected by Bayer as one of the Finalists of this year's G4A Growth.

Read more

New Year, New Offices, Inspiring Innovation!

Careers

Join Our Team

"Using Voice to Save Lives", Cardiokol enabling mass prevention of strokes and chronic complications over time in at-risk populations using voice-based markers for telemonitoring & screening. We offer revolutionary affordable, scalable, long-term and age-friendly monitoring solutions. Our technology is applicable for mass at-risk populations including older adults (65+), by utilizing proprietary technology that is implemented in speech platforms such as landlines, smartphones, smart speakers and voice assistants. Cardiokol long-term strategic offering is a novel platform and a suite of solutions which allow for the first-time wide scale prevention of multiple conditions, starting with Afib including prevention of acute and chronic dire complications (stroke, cardiac and kidney failure and more), at a later stage, Arrhythmias, Heart diseases and Acute Chronic disease.

The speech algorithms team develops the core vocal bio-markers technology for our monitoring platform. The team responsibilities include voice feature analysis algorithms for monitoring and mass screening at scale for chronic medical conditions utilizing voice signal processing and AI (deep learning – DNN).

You will work as an algorithm developer in the team. The position is very hands-on and requires developing an in-depth understanding of the challenges within the voice platform, crafting creative solutions and implementing them. The work involves tight collaboration with the clinical and product teams.

  1. Senior Algorithm Developer

    Airport City, Israel

  2. Junior Algorithm Developer

    Airport City, Israel


Contact Us

Healthcare providers, insurers, telecom, tele-monitoring & tele-health companies, we’ll be happy to collaborate with you!

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.